RxDoctor Payments Data

Nicole Dupree

Acute Care · Waterloo, IANPI 1952974925

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. E.r. Squibb & Sons, L.L.C. accounts for 85.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $918 and has fallen 64.2% since, to $328 in 2025. Among acute care clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,856in general payments, 2019–2025

Across 164 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Pfizer$166
  • Astellas Pharma US Inc$102
  • Boehringer Ingelheim$88
  • Novartis$55
  • Merck$13

What the payments were for

  • Food & beverage$2,77697%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,856 in reported general payments places this provider in the 90th percentile of 104 acute care providers in Iowa.

See all acute care providers in Iowa

Medicare billing

Part B allowed, 2024
$57,502
Medicare patients
168
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$35,244
XareltoRivaroxaban47$16,369
JardianceEmpagliflozin17$6,159
MyrbetriqMirabegron11$4,621
Memantine Hcl40$1,591
Pantoprazole Sodium116$1,559
Atorvastatin Calcium105$1,444
Potassium Chloride113$1,422
Duloxetine Hcl78$1,418
PrevaliteCholestyramine18$1,391
Rosuvastatin Calcium22$1,371
Levothyroxine Sodium118$1,269
Metoprolol Succinate81$1,106
Tamsulosin Hcl53$900
Levetiracetam19$842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$35,244121 claims
Boehringer IngelheimJardiance$88$6,15917 claims
Astellas Pharma US IncMyrbetriq$102$4,62111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 acute care providers in Iowa.

Other acute care in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →